Skip to content
Screener

Celldex Therapeutics CLDX Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue-
EPS-$1.01Miss by $0.13
EPS estimate-$0.88

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$722.6K
EPS estimate-$1.02

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$73.6M-41.2%
Net income-$67.0M-59.2%
EPS (diluted)-$1.01-57.8%

Balance sheet

See full
Cash & equivalents$36.0M-1.0%
Total debt$2.6M-15.1%
Total equity$598.4M-23.9%
Total assets$648.4M-21.2%

Cash flow

See full
Operating cash flow-$48.6M+12.1%
CapEx$440.0K-19.3%
Free cash flow-$49.1M+12.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.72B-23.8%
Enterprise value$1.68B-24.1%
P/S660.7×+435×

Profitability

See full
Operating margin-9,855.4%-12,872pp
Net margin-8,635.8%-11,040pp
FCF margin-6,987.3%-9,941pp

Returns & leverage

See full
Return on equity-32.4%+3.1pp
Debt / equity0×0.0×
Current ratio13×-11.3×

Segments

By product

See full
Grant--100%
Service--100%

FAQ

When did Celldex Therapeutics report Q3 2025 earnings?
Celldex Therapeutics (CLDX) reported Q3 2025 earnings on November 10, 2025 before market open.
What were Celldex Therapeutics's Q3 2025 revenue and EPS?
Celldex Therapeutics reported revenue of - and eps of $-1.01 for Q3 2025.
Did Celldex Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.88 by $0.13.
How did Celldex Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $3.2M a year earlier and eps declined 57.8% from $-0.64.
Where can I find Celldex Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-007179) and the 10-Q periodic report (0001104659-25-109137) directly on SEC EDGAR. The filing index links above go to sec.gov.